Three clinical variables predicted moderate-to-severe esophagitis during esophageal cancer radiotherapy
Tumor location, hypertension and albumin predicted moderate-to-severe acute esophagitis with an internally validated AUC of 0.816.
Tumor location, hypertension and albumin predicted moderate-to-severe acute esophagitis with an internally validated AUC of 0.816.
Both dose rates increased mitochondrial respiration after irradiation, with no clear FLASH-specific mitochondrial phenotype under normoxic conditions.
Automated proton plans reproduced clinical dysphagia and xerostomia estimates closely while reducing optimization time from days to about one hour.
Bullous pemphigoid emerged after seven radiotherapy fractions during pembrolizumab, spreading beyond the treatment field and ultimately preventing completion of both therapies.
EXCERPT At five years, chest wall radiotherapy modestly worsened local symptoms but did not significantly affect overall quality of life or major functional domains.
Without online re-optimization, 65.3% of prostate fractions missed 95% target coverage, with later target expansion strongly linked to coverage loss.
Intent to leave was reported by 51.7%, with team culture, wellbeing and career development independently associated with retention.
Ultra-high dose-rate protons produced fewer DNA breaks at low scavenger concentration, but the effect diminished or reversed under other experimental conditions.
Larger irradiated bowel volumes predicted acute diarrhea after both short-course total neoadjuvant treatment and chemoradiation, although discrimination was modest.
Five-year local control exceeded 89% across proton, photon and stereotactic approaches, with no significant modality effect in meta-regression.
Individual target optimization lowered normal-brain V12 and improved dose gradients while maintaining over 99% coverage, at the cost of higher monitor units.
Baseline miR-144-5p and miR-222-3p differed in patients who later developed greater radiation toxicity, but the signals require validation.
An iridium-192 boost increased median progression-free survival from 8.6 to 11.2 months, without a significant overall-survival improvement.
A prototype stent increased dislodgement resistance 15-fold and demonstrated controllable heating, but proposed radiation-dose benefits remain experimentally untested.
Nine-field intensity-modulated radiotherapy shortened overall planning-plus-delivery time and improved several pelvic dose metrics compared with volumetric modulated arc therapy.